BPH Dual oral therapies: Mechanism and their side effects

BPH dual oral therapy — alpha-blocker and 5-alpha-reductase inhibitor combination, mechanism, and side effects | Dr. Soarawee Weerasopone, urologist at Bangkok Hospital

Benign Prostatic Hyperplasia (BPH) is a degenerative condition of the prostate gland that no aging gentleman can escape. According to epidemiological data, BPH affects 42% of men aged 51–60, over 70% aged 61–70, and nearly 90% aged 81–90. Today we discuss the “dual oral therapies” approach to BPH management. BPH commonly presents with weak urinary […]

en_USEnglish